Quanterix Q4 2025: A Cash-Burn Turnaround Play Hits the Regulatory Fast Lane

Quanterix (NASDAQ: QTRX) reported its fourth-quarter 2025 results, signaling progress toward cash flow breakeven in 2026 after a year of revenue gains but meaningful operating burn. The company posted Q4 revenue of $43.9 million (up 25% year over year) and finished 2025 with about $121.6 million in cash, cash equivalents, marketable securities, and restricted cash. Full-year revenue came in at $138.9 million, with an adjusted EBITDA loss of $44.9 million for the year. Analysts will look for the implied EPS trajectory and whether the cash burn comes down enough to deliver an actual earnings surprise in 2026.

Note: the release does not provide GAAP or non-GAAP EPS figures, so investors will gauge earnings potential through the lens of cash flow, gross margins, and the trajectory toward profitability. The presence of an earnings surprise in earnings narratives will hinge on how quickly order volumes, pricing, and cost controls translate into cash-positive operations.

Fourth Quarter Highlights

Revenue of $43.9 million, up 25% from the prior year.
GAAP gross margin of 45.7%; adjusted gross margin (non-GAAP) of 50.0%.
Adjusted EBITDA loss of $7.9 million.
Cash and equivalents in Q4: $121.6 million at quarter-end, versus guidance of about $120 million.

Full-Year 2025 Highlights

Revenue: $138.9 million, up 1% vs. prior year.
GAAP gross margin: 46.8%; adjusted gross margin (non-GAAP): 47.3%.
Adjusted EBITDA (non-GAAP) loss: $44.9 million.
Ending cash position: $121.6 million; adjusted cash usage in 2025: $30.9 million (vs. $32.2 million prior year).

Operational and Business Highlights

The company outlined a strategic expansion in diagnostics, including a January 2026 submission of a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test for Alzheimer’s disease. Management framed this milestone as a key step in enabling broader, non-invasive diagnostic capabilities.

On the reimbursement front, CMS established a pricing signal of $897 for Quanterix’s LucentAD Complete test, aiming to facilitate claims submissions under the Clinical Laboratory Fee Schedule. That reimbursement benchmark could influence future demand and utilization, particularly as the company allocates resources to clinical validation and adoption.

What the results portend for QTRX and sector peers

The near-term focus remains: can Quanterix convert revenue growth into cash flow relief fast enough to turn an adjusted EBITDA loss into a path to breakeven in 2026? The Q4 beat on revenue is a positive signal, but the margin compression (GAAP gross margin down versus prior year) underscores ongoing cost-cum-capital investments in R&D and commercialization. In Matt Levine’s world, this is a classic “bet on the cadence” moment—the company needs an operating rhythm where higher volumes and a stable product mix outpace rising costs.

For the broader in vitro diagnostics and neurodegenerative diagnostics space, the combination of a regulatory milestone (510(k) pathway) and a CMS reimbursement floor introduces a blueprint for how early-stage diagnostic players might scale: validate clinically meaningful performance, secure payer coverage signals, and compress cash burn through disciplined operating leverage. If Quanterix achieves sustained breakeven cash flow, peers with similar burn rates and product silos could be forced to reassess funding strategies or accelerate partnerships.

Analyst lens and forward-looking considerations

Given the absence of explicit GAAP EPS in the press release, EPS and its consensus are left to the market’s interpretation of cost structure and the precision of the company’s non-GAAP adjustments. The EPS consensus for Quanterix will likely hinge on how quickly the company can bring the Adjusted EBITDA loss toward zero, and whether the cadence of product launches and reimbursement milestones translates into a step-change in profitability.

The January 510(k) filing and the CMS reimbursement development may be interpreted as signals that management believes the company can create durable demand for its high-sensitivity biomarker platform. If the path to cash flow breakeven remains on track into 2026, investors could reframe the revenue forecast and earnings potential for the next several quarters, particularly if additional diagnostics wins or expanded partnerships emerge.

Risks and caveats

The numbers reflect a narrative of growth with ongoing burn. The company’s ability to sustain topline gains, improve gross margins, and manage cash usage will shape the likelihood of a genuine earnings surprise in the quarters ahead. As always, execution risk, regulatory timing, and payer dynamics are the X-factors that separate a hopeful trajectory from a durable path to profitability.

Investors should watch for any forward-looking statements on 2026 operating targets, as well as updates on the progress of the Alzheimer’s diagnostics program and the payer landscape surrounding high-sensitivity tests.